This is a prospective genetically-stratified randomized double-blind event-driven multicentre
clinical trial to assess the efficacy of posaconazole-based antifungal prophylaxis allocation
strategies for patients with acute myeloid leukemia who receive induction chemotherapy.
Allocation strategy based on an invasive mold infection genetic risk will be double-blinded.